Teva moves closer to a drug for celiac disease with positive Phase 2 results

Teva's experimental antibody TEV-408 showed positive Phase 2a results in preventing intestinal damage in celiac disease patients, with potential annual revenues estimated at $1 billion if approved. The drug targets the underlying immune cause by blocking IL-15 and has Fast Track designation from the FDA.

This Wire brief sits within Fusion42's coverage of Biotech.